Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5837 plus odronextamab in adults with aggressive B-cell non-Hodgkin lymphoma
NL-OMON60261Phase 1Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of REGN5837 and odronextamab in mature B-cell lymphoma, sponsored by Regeneron Pharmaceuticals. Started May 2024; status: recruiting.
02
Drugs
REGN5837odronextamab
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON60261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60261.